Dec. 15, 2022
LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the company’s second hearing restoration candidate for sensorineural hearing loss (SNHL). FX-345 is a combination of two small